Zydus Lifesciences Limited has informed the Exchange regarding a press release dated July 15, 2025, titled "Zydus receives final approval from USFDA for Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg".
Press Release Jul 15 2025
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Celecoxib Capsules in various dosages. Celecoxib is a nonsteroidal anti-inflammatory drug used to treat pain and inflammation from conditions like arthritis and menstrual pain. The capsules will be produced at Zydus Lifesciences' facility in Ahmedabad, and the product had significant annual sales in the United States. This filing serves to inform investors and the stock exchange about the approval and its implications for the company.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Jun 18 2025
- Press Release Jun 11 2025
- Press Release Jun 10 2025
- Press Release Jun 02 2025
- Press Release May 28 2025
Later from Zydus Lifesciences
- Press Release Jul 16 2025
- Press Release 17-07-2025 NewspaperpublicationAGMnotice17072025
- Press Release Jul 24 2025
- Press Release Jul 29 2025
- Press Release Aug 07 2025
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences